Search results
EyePoint Pharmaceuticals’ stock plunges as eye treatment fails to meet trial goal
Market Watch· 3 days agodropped nearly 30% in premarket trading Monday after the company said its experimental...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 4 hours ago“Our top priority is executing on our strategy to accelerate the development and delivery of transformative medicines for patients, and we are confident that we can accomplish this mission while ...
Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms
Investor's Business Daily· 7 days agoRegeneron stock jumped Thursday, bolstered by strong sales of a high-dose version of its blockbuster...
EyePoint Pharmaceuticals Trial of Duravyu in Diabetic Eye Disease Fails to Meet Primary Endpoint
Market Watch· 3 days agoEyePoint Pharmaceuticals said that topline results from a Phase 2 clinical trial evaluating Duravyu in non-proliferative diabetic retinopathy didn't meet the pre-specified primary endpoint.
HanAll Biopharma initiates Phase III DED treatment trial
Clinical Trials Arena via Yahoo Finance· 3 days agoHanAll Biopharma has commenced the Phase III VELOS-4 trial for tanfanercept, a new topical...
Xeris Biopharma sees 1Q revenue jump on strength of product sales
Proactive Investors· 7 hours agoXeris Biopharma Holdings (NASDAQ:XERS) revealed a robust growth trajectory in its first quarter,...
Earnings call: Tarsus reports strong Q1 with XDEMVY sales surge By Investing.com
Investing.com· 6 hours agoTarsus Pharmaceuticals, Inc. (TARS) has revealed robust financial results for the first quarter of...
...Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for...
FOX 4 Kansas City· 6 days agoHanAll has initiated a Phase III VELOS-4 study to evaluate the efficacy and safety of tanfanercept in dry eye based on the findings from the previous Phase III VELOS-3 study. Tanfanercept demonstrated ...
Ocular Therapeutix Inc Reports First Quarter 2024 Earnings
Guru Focus· 2 days agoRevenue: Reported $14.8 million, a 10.4% increase year-over-year, falling short of the estimated $15.41 million.Net Loss: Increased to $(64.8) million from $(3
Ocular Therapeutix Inc Reports First Quarter 2024 Earnings
GuruFocus.com via Yahoo Finance· 2 days agoThe company, a prominent biopharmaceutical entity focused on innovative therapies for eye diseases,...